Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Fordyce says he attends the IgA nephropathy Foundation’s annual meeting and is the only biotech CEO who shows up to listen. Patients ask how they will get access to new medicines. He calls these exchanges sometimes awkward but argues companies should face patients and hold the business accountable.

Related Insights

The commercial function isn't just marketing. Its critical purpose is to ensure the healthcare delivery system is equipped to receive a new therapy. A great product is merely "table stakes"; adoption hinges on overcoming systemic barriers between regulatory approval and actual patient access.

Fordyce says he has no MBA but knows business is people and money. He states plainly that 'no cash, no company,' and because biotech mostly raises through equity, CEOs must be disciplined about stock price and financing. He sees that as a core CEO job alongside organizing people and time around translation.

Ikarovec's CEO, a part-time ophthalmologist, sees patients reject current treatments for geographic atrophy due to high treatment burden and limited benefit. This direct experience validates the market's unmet need, providing a powerful, firsthand perspective that strengthens the company's mission and investor pitch.

The pharmaceutical industry is often misunderstood because it communicates through faceless corporate entities. It could learn from tech's "go direct" strategy, where leaders tell compelling stories. Highlighting the scientists and patient journeys behind breakthroughs could dramatically improve public perception and appreciation.

Bio CEO John Crowley defines "winning" in the biotech race as a two-part victory. It's not enough to lead in scientific discovery; the US must also dismantle systemic barriers like insurance hurdles and high out-of-pocket costs to ensure Americans can access these advanced medicines.

When offered a chance for his daughter Grace to receive a one-off experimental drug, CEO Matt Wilsey refused, operating on an "all of us or none of us" principle. This demonstrates a community-first ethical framework in patient-led drug development, prioritizing collective benefit over individual gain.

Fordyce says Vera’s patient focus started before trials by choosing autoimmune disease and a mechanism aimed at inadequate standard of care. He points to steroid side effects—acute and chronic—as a real patient problem. He argues listening to patients reveals these harms and should shape target selection, not just marketing.

A former medic explains that hands-on patient care provides an irreplaceable perspective for executives. It grounds strategic decisions in the reality of the patient experience, which is crucial for communicating value to teams and investors and maintaining a patient-first culture.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.

While a CEO's personal connection to a disease provides powerful motivation, it can raise investor concerns about objectivity. Zag Bio's CEO addresses this by emphasizing a rigorously data-driven approach to all pipeline decisions, ensuring patient focus does not lead to biased choices.